Opinion

Video

Guiding Patients Through Third-Line mCRC Therapy Decisions

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Video content above is prompted by the following:

When discussing treatment selection in the third-line setting for metastatic colorectal cancer, how do you frame this conversation with patients, balancing efficacy, safety, and overall prognosis?

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Related Content
Kidney illustration | Image Credit: Tom - stock.adobe.com
December 2nd 2024

CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity

Brooke McCormick
The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Immunotherapy | Image Credit: © kentoh-stock.adobe.com
December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
3d illustration of a b cell-sebastianlaulitzki-stock.adobe.com.jpeg
November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor
The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Blood journal | Image credit: American Society of Hematology
November 29th 2024

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

Mary Caffrey
A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo